These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 34537847)

  • 41. Is 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Combined With 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) Superior to PPSV23 Alone for Reducing Incidence or Severity of Pneumonia in Older Adults? A Clin-IQ.
    Hayward S; Thompson LA; McEachern A
    J Patient Cent Res Rev; 2016; 3(2):111-115. PubMed ID: 27376105
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.
    Cho BH; Stoecker C; Link-Gelles R; Moore MR
    Vaccine; 2013 Dec; 31(50):6011-21. PubMed ID: 24148572
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children.
    Angoulvant F; Levy C; Grimprel E; Varon E; Lorrot M; Biscardi S; Minodier P; Dommergues MA; Hees L; Gillet Y; Craiu I; Zenkhri F; Dubos F; Guen CG; Launay E; Martinot A; Cohen R
    Clin Infect Dis; 2014 Apr; 58(7):918-24. PubMed ID: 24532543
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccination.
    Cannon K; Elder C; Young M; Scott DA; Scully IL; Baugher G; Peng Y; Jansen KU; Gruber WC; Watson W
    Vaccine; 2021 Dec; 39(51):7494-7502. PubMed ID: 34839993
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Strategies for pneumococcal vaccination in older adults in the coming era.
    Nakashima K; Fukushima W
    Hum Vaccin Immunother; 2024 Dec; 20(1):2328963. PubMed ID: 38517265
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Incidence, aetiology and serotype coverage for pneumococcal vaccines of community-acquired pneumonia in adults: a population-based prospective active surveillance study in Brazil.
    Duarte FG; Barberino MG; da Silva Moreira S; Reis JN; Spinardi JR; de Almeida RS; Allen KE; Alexander-Parrish R; Brim R; de Araújo Neto CA; Moreira ED
    BMJ Open; 2022 Apr; 12(4):e059824. PubMed ID: 35428648
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review.
    Torres A; Cillóniz C; Blasi F; Chalmers JD; Gaillat J; Dartois N; Schmitt HJ; Welte T
    Respir Med; 2018 Apr; 137():6-13. PubMed ID: 29605214
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pneumococcal conjugate vaccine use in adults - Addressing an unmet medical need for non-bacteremic pneumococcal pneumonia.
    Sings HL
    Vaccine; 2017 Sep; 35(40):5406-5417. PubMed ID: 28602602
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pneumococcal conjugate vaccine use for the prevention of pneumococcal disease in adults <50 years of age.
    Isturiz RE; Hall-Murray C; McLaughlin JM; Snow V; Schmoele-Thoma B; Webber C; Thompson A; Scott DA
    Expert Rev Vaccines; 2018 Jan; 17(1):45-55. PubMed ID: 29183235
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Prevention of Streptococcus pneumoniae (pneumococcal) infections in adults].
    Ludwig E; Mészner Z;
    Orv Hetil; 2014 Dec; 155(50):1996-2004. PubMed ID: 25481502
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of 23-Valent Pneumococcal Polysaccharide Vaccine Inoculated During Anti-Cancer Treatment Period in Elderly Lung Cancer Patients on Community-Acquired Pneumonia Hospitalization: A Nationwide Population-Based Cohort Study.
    Chiou WY; Hung SK; Lai CL; Lin HY; Su YC; Chen YC; Shen BJ; Chen LC; Tsai SJ; Lee MS; Li CY
    Medicine (Baltimore); 2015 Jul; 94(26):e1022. PubMed ID: 26131806
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 23-Valent Pneumococcal Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to Vaccine-Type
    Chandler T; Furmanek S; Carrico R; Balcom D; Arnold F; Ramirez J
    Microorganisms; 2022 Mar; 10(3):. PubMed ID: 35336135
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluating the cost-effectiveness of a sequential pneumococcal vaccination compared to single-dose vaccination strategy for adults in Hong Kong.
    Shami JJP; Pathadka S; Chan EW; Hui J; Sato R; Patil S; Li X
    Hum Vaccin Immunother; 2020 Aug; 16(8):1937-1944. PubMed ID: 31977268
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevention of adult pneumococcal pneumonia with the 13-valent pneumococcal conjugate vaccine: CAPiTA, the community-acquired pneumonia immunization trial in adults.
    Isturiz R; Webber C
    Hum Vaccin Immunother; 2015; 11(7):1825-7. PubMed ID: 26076136
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older.
    Buchwald UK; Andrews CP; Ervin J; Peterson JT; Tamms GM; Krupa D; Ajiboye P; Roalfe L; Krick AL; Sterling TM; Wang M; Martin JC; Stek JE; Kohn MA; Folaranmi T; Abeygunawardana C; Hartzel J; Musey LK;
    Hum Vaccin Immunother; 2021 Aug; 17(8):2678-2690. PubMed ID: 34019468
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of the pediatric 13-valent pneumococcal conjugate vaccine on serotype distribution and clinical characteristics of pneumococcal pneumonia in adults: The Japan Pneumococcal Vaccine Effectiveness Study (J-PAVE).
    Sando E; Suzuki M; Furumoto A; Asoh N; Yaegashi M; Aoshima M; Ishida M; Hamaguchi S; Otsuka Y; Morimoto K
    Vaccine; 2019 May; 37(20):2687-2693. PubMed ID: 30975569
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A population-based analysis to determine the impact of the 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in British Columbia, Canada.
    Vadlamudi NK; Patrick DM; Rose C; Sadatsafavi M; Hoang L; Marra F
    Vaccine; 2022 Feb; 40(7):1047-1053. PubMed ID: 35012778
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pneumococcus and the Elderly in Italy: A Summary of Available Evidence Regarding Carriage, Clinical Burden of Lower Respiratory Tract Infections and On-Field Effectiveness of PCV13 Vaccination.
    Orsi A; Ansaldi F; Trucchi C; Rosselli R; Icardi G
    Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27428964
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pneumococcal Vaccination Among Medicare Beneficiaries Occurring After the Advisory Committee on Immunization Practices Recommendation for Routine Use Of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults Aged ≥65 Years.
    Black CL; Williams WW; Warnock R; Pilishvili T; Kim D; Kelman JA
    MMWR Morb Mortal Wkly Rep; 2017 Jul; 66(27):728-733. PubMed ID: 28704347
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of PCV7/PCV13 introduction on community-acquired alveolar pneumonia in children <5 years.
    Greenberg D; Givon-Lavi N; Ben-Shimol S; Ziv JB; Dagan R
    Vaccine; 2015 Aug; 33(36):4623-9. PubMed ID: 26116251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.